These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35096477)

  • 1. Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.
    Busner J; Pandina G; Domingo S; Berger AK; Acosta MT; Fisseha N; Horrigan J; Ivkovic J; Jacobson W; Revicki D; Villalta-Gil V
    Innov Clin Neurosci; 2021; 18(10-12):15-22. PubMed ID: 35096477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.
    Pandina GJ; Busner J; Kempf L; Fallon J; Alphs LD; Acosta MT; Berger AK; Day S; Dunn J; Villalta-Gil V; Grabb MC; Horrigan JP; Jacobson W; Kando JC; Macek TA; Singh MK; Stanford AD; Domingo SZ
    Innov Clin Neurosci; 2024; 21(1-3):52-60. PubMed ID: 38495603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
    Busner J; Pandina G; Day S; Mahableshwarkar A; Kempf L; Sheean M; Dunn J
    Innov Clin Neurosci; 2023; 20(1-3):25-31. PubMed ID: 37122576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development.
    Harvey PD; Busner J; Pandina G; Taylor HG; Grabb M; Jimenez-Shahed J
    Innov Clin Neurosci; 2023; 20(1-3):13-17. PubMed ID: 37122579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials.
    Burton BK; Skalicky A; Baerwald C; Bilder DA; Harding CO; Ilan AB; Jurecki E; Longo N; Madden DT; Sivri HS; Wilcox G; Thomas J; Delaney K
    Mol Genet Metab Rep; 2021 Dec; 29():100810. PubMed ID: 34815941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases.
    Lanar S; Acquadro C; Seaton J; Savre I; Arnould B
    Orphanet J Rare Dis; 2020 Jun; 15(1):134. PubMed ID: 32493385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
    Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
    Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Pediatric Initiatives on CNS Drug Development for All Ages-2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
    Pandina G; Busner J; Horrigan JP; McSherry C; Bateman-House A; Pani L; Kando J
    Innov Clin Neurosci; 2023; 20(1-3):18-24. PubMed ID: 37122578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The art and science of choosing efficacy endpoints for rare disease clinical trials.
    Cox GF
    Am J Med Genet A; 2018 Apr; 176(4):759-772. PubMed ID: 29423972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding studies in drug development for rare genetic diseases.
    Wang L; Wang J; Feng J; Doi M; Pepe S; Pacanowski M; Schuck RN
    Orphanet J Rare Dis; 2022 Apr; 17(1):156. PubMed ID: 35382851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
    Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
    Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.
    Kakkis ED; O'Donovan M; Cox G; Hayes M; Goodsaid F; Tandon PK; Furlong P; Boynton S; Bozic M; Orfali M; Thornton M
    Orphanet J Rare Dis; 2015 Feb; 10():16. PubMed ID: 25757705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can registries contribute to the development and evaluation of CNS therapeutics?
    Severe JB; Stemhagen A
    Innov Clin Neurosci; 2013 May; 10(5-6 Suppl A):29S-31S. PubMed ID: 23882432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
    Di Paolo A; Arrigoni E
    Drugs; 2018 Mar; 78(4):399-410. PubMed ID: 29464665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do patients and other members of the public engage with the orphan drug development? A narrative qualitative synthesis.
    Frost J; Hall A; Taylor E; Lines S; Mandizha J; Pope C
    Orphanet J Rare Dis; 2023 Apr; 18(1):84. PubMed ID: 37069597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
    Maeda K; Kaneko M; Narukawa M; Arato T
    Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.